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   ABSTRACT 
  Objective      AMELIA (OsteoArthritis Modifying Effects 
of Long-term Intra-articular Adant) was designed to 
compare against placebo the efﬁ  cacy and safety of 
repeated injections of hyaluronic acid (HA) and its effect 
on disease progression over 40 months.   
  Methods      A multicentre, randomised, patient and 
evaluator-blinded, controlled study in 306 patients 
fulﬁ  lling American College of Rheumatology criteria for 
knee osteoarthritis, radiological grades II–III (Kellgren–
Lawrence) and joint space width ≥2 mm. Patients 
received four cycles of ﬁ  ve intra-articular HA or placebo 
injections with a follow-up of 6 months after the ﬁ  rst 
and second cycles, and 1 year after the third and fourth 
cycles. Osteoarthritis Research Society International 
(OARSI) 2004 responder criteria were used to assess 
efﬁ  cacy. The consumption of rescue medication was a 
secondary outcome. Adverse events were recorded for 
safety purposes.   
  Results      At the 40-month visit signiﬁ  cantly more patients 
responded to HA compared with placebo (OARSI 2004, 
p=0.004). The number of responders to HA increased 
through the study, whereas those to placebo did not 
change. Signiﬁ  cant differences were also found in favour 
of HA for each individual component of the OARSI 2004. 
No safety problems were recorded.   
  Conclusions      The results of AMELIA offer pioneer 
evidence that repeated cycles of intra-articular injections 
of HA not only improve knee osteoarthritis symptoms 
during the in-between cycle period but also exert a 
marked carry-over effect for at least 1 year after the last 
cycle. In this respect, it is not possible to establish if this 
carry-over effect reﬂ  ects true osteoarthritis remission or 
just a modiﬁ  cation of the disease’s natural course. 
  ClinicalTrials.gov number, NCT00669032      
  Osteoarthritis is a chronic disorder characterised by 
joint cartilage degeneration as the central feature 
associated with concomitant changes in synovium 
and subchondral bone metabolism.    1    Osteoarthritis 
of the knee, the principal large joint to be affected, 
results in disabling symptoms in 10% of people 
older than 55 years, a quarter of whom are severely 
affected.    2    Most current pharmacological options 
are limited to alleviating pain and improving func-
tional activity but effective therapeutic alternatives 
to slow disease progression are also needed. 
  Hyaluronic acid (HA) is a key molecule in joint 
biomechanics. In osteoarthritis and other arthropa-
thies, the reduction in concentration and molecu-
lar weight of endogenous HA greatly alters the 
properties of the synovial ﬂ  uid, causing cartilage 
damage and worsening osteoarthritis symptoms.    3    
Treatment with exogenous HA contributes to 
restoring the elastic and viscous properties of the 
synovial ﬂ   uid, resulting in pain reduction and 
functional improvement. Besides this mechani-
cal action, different studies have conﬁ  rmed  that 
HA interacts with mediators of inﬂ  ammation and 
matrix turnover in joint cells, reduces the apoptosis 
of chondrocytes and exerts a biosynthetic chondro-
protective effect.    4     –      9    
  This dual mechanism of action may account for 
the particular effect of HA on clinical symptoms of 
osteoarthritis. Unlike traditional analgesics and non-
steroidal anti-inﬂ  ammatory drugs (NSAID), HA is 
not a rapidly acting agent, but its clinical efﬁ  cacy 
on pain and function shows a carry-over effect that 
extends the results for a long time after the admin-
istration is stopped, identifying it as a symptomatic 
slow-acting class compound (SYSADOA).    10        11    
  Although the use of intra-articular HA injections 
for the relief of pain in people with knee osteoar-
thritis is recommended by scientiﬁ  c societies,    12        13    
the characteristics of the patients who are most 
likely to beneﬁ  t from this treatment need to be 
deﬁ  ned appropriately, and the role of HA in dis-
ease progression is still under discussion.    12     –      15    
Unfortunately, the lack of long-term studies con-
tributes to this uncertainty. In addition, the variety 
of HA have different physicochemical characteris-
tics and thus cannot be expected to have the same 
clinical effect.    4        16        17    
  The current trial AMELIA (OsteoArthritis 
Modifying Effects of Long-term Intra-articular 
Adant) was conducted to compare the efﬁ  cacy and 
safety of repeated injections of HA compared with 
placebo over a period of 40 months. 
  METHODS 
  Study  design 
  This was a randomised, patient and evaluator 
blinded, placebo-controlled study with parallel 
groups. Patients with osteoarthritis of the knee 
were randomly assigned to receive   intra-articular 
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  Main exclusion criteria were body mass index greater than 
32   kg/m  2  , a history of trauma or surgery in the target knee, 
arthroscopy surgery during the year before inclusion, joint 
inﬂ   ammatory diseases and/or microcrystalline arthropathies, 
coagulation/platelet disorders or any concomitant disease that 
could interfere with the evaluation. The administration of intra-
articular steroids in the previous 3 months, HA injections during 
the past year or NSAID treatment during 2 weeks before inclu-
sion were also reasons for exclusion.   
  Evaluation  of  efﬁ  cacy 
  The primary efﬁ  cacy outcome was the percentage of subjects 
with a clinical response according to Osteoarthritis Research 
Society International (OARSI) 2004 criteria    20    at the end of 
follow-up. Patients were classiﬁ   ed as responders if the pain 
or physical function score decreased at least 50% and at least 
20   mm on the VAS, or if two of the following three ﬁ  ndings 
were recorded: a decrease in pain of at least 20% or at least 10 
mm on the VAS, a decrease in physical function of at least 20% 
and at least 10 mm on the VAS, or an increase in the score of the 
patient’s global assessment by at least 20% and at least 10 mm 
on the VAS. 
  Secondary outcomes included the percentage of subjects with 
clinical response according to OMERACT–OARSI criteria at 
each follow-up visit; each component of OMERACT–OARSI 
(reduction in pain, improvement in function using the Western 
Ontario and McMaster Universities Osteoarthritis Index func-
tion subscale and in patients’ global assessment (all of them 
measured using VAS) and consumption of rescue medication for 
osteoarthritis (paracetamol and NSAID) throughout the study).   
  Evaluation  of  safety 
  Treatment safety and tolerability was evaluated based on the 
incidence and type of adverse events (with special attention to 
allergic reactions such as skin rash, urticaria, pruritus, swelling 
and/or erythema) and the results of blood laboratory tests and 
physical examinations throughout the duration of the study. 
Safety analyses were performed in those patients who received 
at least one intra-articular injection (safety population).   
  Statistical  methods 
  The study was designed to have a statistical power of 80% to 
detect a difference of at least 20% of patients responding to 
treatment compared with placebo (expected response rate up to 
30%), with a two-sided signiﬁ  cance level of less than 5%. Given 
the speciﬁ  ed statistical power and assuming up to a 40% drop-
out rate, the study was planned to include a total of 300 patients 
(150 per treatment arm). 
injections of 2.5 ml 1% sodium hyaluronate with a mean 
  molecular weight of 900 000 daltons, obtained through a fermen-
tation process from strains of   Streptococcus zoopidemicus   (Adant; 
Tedec-Meiji Farma, Madrid, Spain) or placebo injections (2.5 ml 
of saline solution). The study consisted of four treatment cycles 
of ﬁ  ve weekly injections each one. The follow-up periods were 
6  months long after the ﬁ  rst and second cycles and 1 year long 
after the third and fourth cycles, resulting in a total study dura-
tion of 40 months (  ﬁ  gure 1  ). The repeated cycles were adminis-
tered regardless of whether the patients had symptoms or not.   
  Both treatments were packaged identically in order to main-
tain the blinding conditions. A computer-generated randomised 
list was used to provide balanced blocks of four patients each. 
Allocation to treatment as well as efﬁ  cacy and safety evalua-
tion was performed by a blinded physician, while an unblinded 
physician was responsible for treatment administration. The 
injections were non-ultrasound guided and three approaches 
were permitted: medial/lateral (extended knee) and infrapatellar 
(ﬂ  exed knee). 
  At the screening visit the patients were assessed by the 
blinded physician for fulﬁ   lment of the entry criteria, demo-
graphic characteristics and medical history. Knee radiographs 
were also obtained. Eligible patients were randomly assigned 
1:1 to receive intra-articular injections of HA or placebo. In the 
case of bilateral affectation only the more symptomatic knee at 
baseline was considered for the study, although the other knee 
could be treated with the same assigned treatment. Patients 
with effusion had the joint aspirated before the administration 
of treatment. Concomitant medications for chronic pathologies 
other than osteoarthritis were also recorded. Acetylsalicylic acid 
(maximum 300 mg/day) for vascular prevention, paracetamol up 
to 4 g/day as rescue medication as well as short cycles of NSAID 
were permitted. However, for 24 h and 1 week before efﬁ  cacy 
evaluation, patients were required to abstain from any parac-
etamol or NSAID, respectively. During the whole study period 
corticosteroid injections were not permitted in the target knee. 
Only two injections were allowed in the contralateral knee if 
necessary and no more than two injections per year in any other 
joint than the knee.   
    Patients’ inclusion and exclusion criteria 
  Eligible patients were men and women of at least 45 years of 
age with knee osteoarthritis in the medial tibiofemoral com-
partment according to the American College of Rheumatology    18    
with grade II to III radiographic stage osteoarthritis    19    and mini-
mum medial femorotibial joint space width of the target knee of 
2 mm or greater. Patients were required to have pain of 55 mm 
or greater on a visual analogue scale (VAS) at any time during the 
week before inclusion. 
 Figure  1        Study diagram. HA, hyaluronic acid; i.a., intra-articular.       
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total of 77.85% of HA patients and 82.24% in the placebo group 
had bilateral osteoarthritis (p=0.341). Of them, 55.17% of HA 
patients and 56.02% of the placebo group (p=0.7992) were also 
treated in the contralateral knee. No differences between groups 
were found related to the administration approach.     
  Treatment  efﬁ  cacy 
  At the end of follow-up (40 months) signiﬁ  cantly more patients 
receiving HA responded to treatment in comparison with 
  For quantitative variables, mean, median, SD, maximum and 
minimum values were calculated. Student’s t test was used to 
compare independent variables following a normal distribution 
and the Mann–Whitney U test was used if the applicability con-
ditions were not present. Qualitative variables were expressed 
as total number and relative frequencies. Pearson’s χ  2   test was 
used for comparisons of frequencies between groups. 
  The main study population included all randomly assigned 
patients with at least one efﬁ  cacy assessment after randomisa-
tion (the modiﬁ  ed intention-to-treat population). A sensitivity 
analysis was performed to assess the imputation method for 
handling missing data using the mixed method of repeated mea-
sures and the last observation carried forward. The last observa-
tion carried forward proved to be the more conservative method 
and was then applied. All statistical tests were performed using 
SAS software version 9.2.     
  RESULTS 
    Disposition of patients and demographic characteristics 
  Recruiting started in October 2003 and the last follow-up was 
performed on July 2009. The 19 participating centres screened 
a total of 446 patients, of whom 140 (31.4%) were screening 
failures. Five patients did not provide any efﬁ  cacy data after ran-
domisation and were not included in the analysis of efﬁ  cacy, 
leaving a total of 301 patients in the intention-to-treat popula-
tion. A total of 109 and 94 patients receiving HA or placebo, 
respectively, completed the study (  ﬁ  gure 2  ).   
  The clinical and demographic characteristics of the patients did 
not differ at baseline (  table 1  ). Overall, the great majority of the 
patients were women (83.7%) the mean age was 63.4  years, with 
a body mass index of 28.6. The mean duration of knee osteoarthri-
tis was 7.5 years and a mean joint space width value of 3.5  mm. A 
  Table  1         Demographic and baseline clinical characteristics of study 
groups  
   HA  (n=153)   Placebo  (n=153) 
Women, n (%) 128 (83.7) 128 (83.7)
Age, years (mean (SD)) 63 (8.2) 63.9 (8.9)
BMI, kg/m  2   (mean (SD)) 28.4 (2.7) 28.7 (2.6)
Duration knee osteoarthritis, years (mean (SD)) 6.9 (6.8) 8.1 (8.4)
Osteoarthritis baseline characteristics
  Pain, VAS 0–100 (mean (SD)) 69.7 (11.1) 71.2 (11.2)
  Morning stiffness, <30 min (n (%)) 142 (92.8) 133 (86.9)
  Joint crackles, n (%) 141 (92.2) 138 (90.2)
Kellgren–Lawrence grade, n (%)
  II 108 (70.6) 114 (74.5)
  III 45 (29.4) 39 (25.5)
Joint space width, mm (mean (SD)) 3.5 (0.82) 3.5 (0.89)
WOMAC, VAS 0–100 (mean (SD))
  Total 55.7 (15.5) 58.2 (14.7)
  Pain 56.0 (16.7) 56.7 (15.2)
  Stiffness 54.8 (23.0) 54.8 (22.4)
 Function 57.1 (17.0) 59.1 (15.1)
      BMI, body mass index; HA, hyaluronic acid; VAS, visual analogue scale; WOMAC, 
Western Ontario and McMaster Universities Osteoarthritis Index.     
 Figure  2        Patients’ disposition for clinical assessment. JSW, joint space width.       
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the degree of improvement in the HA group was signiﬁ  cantly 
higher compared with placebo (p values 0.025, 0.023 and 0.002, 
respectively) (  table 2  ).   
  A total of 26.8% of patients receiving HA did not complete 
the study compared with 38.2% in the placebo group. It is note-
worthy that the number of losses due to lack of efﬁ  cacy were 
signiﬁ  cantly higher in the placebo group (p=0.027). The demo-
graphic and baseline characteristics of completers and dropouts 
were analysed, and no differences were found with the excep-
tion of age in the placebo group, with the completers being 
younger than the dropouts (p=0.047). Aspiration in the target 
knee was performed in 22.82% of patients in the HA group and 
21.05% of the placebo group (p=0.712), with a median of two 
aspirations per patient in both groups during the overall study 
period. 
  Overall, rescue medication (paracetamol/NSAID) was con-
sumed during the study by 71.1% and 71.7% of the HA and pla-
cebo patients, respectively. Paracetamol was consumed by 48% 
of the patients and the mean daily dose during the study experi-
enced a 27% reduction in the HA group compared with baseline 
versus only a 4% reduction in the placebo group (  table   2  ). A 
logistic regression analysis was performed with no differences 
between the HA and placebo (p=0.9129) groups, concluding that 
rescue medication did not interfere with the clinical assessment 
of patients.   
  Safety 
  The number of patients who experienced at least one adverse 
event was the same in both treatment groups, with an overall 
frequency of 83.0%. Twenty-two patients (11 in each group) 
experienced a total of 29 related adverse events. Most of them 
were related to the study intervention, such as local bleeding, 
pain of mild intensity or allergic reaction, none of them was seri-
ous. The frequency and types of related adverse events are sum-
marised in   table 3  . During the overall study period, there were no 
abnormalities in vital signs, clinical ﬁ  ndings or laboratory param-
eters that could be considered as being related to the treatment. 
At the end of the study, 513 and 487 cycles were administered 
in the HA and placebo groups, respectively, providing a rate of 
0.029 related adverse events per cycle in both groups.       
placebo according to OARSI 2004 criteria (p=0.004), the number 
of responders being 22% higher in HA group after the four treat-
ment cycles (RR 1.22, 95% CI 1.07 to 1.41). 
  The number of responders to HA injections progressively 
increased after each treatment cycle (from 71.1% to 80.5%), 
whereas responses to placebo remained fairly stable (from 
67.8% to 65.8%). 
  This progression gave results with strong statistical signiﬁ  -
cance and differences between the two groups from the second 
until the last evaluation at 40 months (  ﬁ  gure 3  ). Among those 
non-responders after the ﬁ  rst cycle, up to 54% of HA and 38% 
of placebo patients evolved positively over the study. At the 
40-month visit the number of responders in this subgroup was 
54% with HA versus 31% in the placebo group, (p=0.026).   
  All of the OARSI components (pain, function and patient global 
assessment) were analysed at the end of the study, showing that 
  Table  2         Summary of results from primary and secondary outcomes 
assessment (intention-to-treat population)   
 
 HA 
(n=149) 
 Placebo 
(n=152)   p  Value 
Primary outcome
  Responders OARSI 2004 
  at end of follow-up, n (%)
120 (80.5) 100 (65.8) 0.004
Secondary outcomes
  Responders OARSI 2004 at each cycle assessments, n (%)
    7 months 106 (71.1) 103 (67.8) 0.525
    14 months 114 (76.5) 99 (65.1) 0.030
    21 months 116 (77.9) 103 (67.8) 0.049
    27 months 116 (77.9) 103 (67.8) 0.049
    34 months 121 (81.2) 99 (65.1) 0.002
  Pain or function reduction 50% 
  (20 mm), n (%)
97 (65.1) 79 (52.0) 0.021
  Overall pain reduction 20% 
  (10 mm), n (%)
118 (79.2) 103 (67.8) 0.025
  Function improvement 20% 
  (10 mm), n (%)
105 (70.5) 88 (57.9) 0.023
  Patient’s global assessment 
  reduction 20% (10 mm), n (%)
111 (74.5) 88 (57.9) 0.002
  Mean consumption of 
  paracetamol, mg/day (SD)
408.8 (644.2) 451.4 (925.8) NS
      HA, hyaluronic acid; OARSI, Osteoarthritis Research Society International.     
 Figure  3        Evolution of responders Osteoarthritis Research Society International, 2004. HA, hyaluronic acid.       
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clinically meaningful and remarkable.    30    The RR used to quantify 
the effect size established a probability of success of HA of 22% 
higher than placebo 1 year after the last cycle was administered. 
  The AMELIA design enables us to gain a better understand-
ing of the clinical response of symptomatic knee osteoarthritis 
patients subject to HA injections by looking for the carry-over 
analgesic effect duration. AMELIA was able to detect symptom-
atic effects even 1 year after the last HA administration cycle, 
giving us unprecedented information about the HA therapeutic 
proﬁ  le. These results are in line with those reported previously, 
granting HA greater efﬁ  cacy than NSAID    23    and than steroids 
after 5–8 weeks post-treatment,    22      33   even though previous stud-
ies do not provide long-term data. We cannot ascertain whether 
the pre-established therapeutic schedule, consisting of adminis-
tering HA even to patients without symptoms, could contribute 
to the carry-over effect, but it could be a plausible explanation. 
In this regard, it is not possible to establish whether this carry-
over effect reﬂ  ects disease remission or just a modiﬁ  cation of the 
natural course of the disease. 
  Overall, the use of rescue medication during the study was 
low. Although the mean paracetamol consumption was 23% 
lower in the HA group, the differences were not statistically sig-
niﬁ  cant, probably due to the high data dispersion. Certainly, the 
way of controlling rescue medication use is a study limitation 
because patients were asked at every assessment visit about the 
frequency and doses of consumption, but it was not delivered 
in hand, leading to insufﬁ  cient recording and an inherent inaccu-
racy. In any case, however, the logistic regression analysis con-
cluded that the use of rescue medication did not interfere with 
the assessment of the clinical outcome. 
  Adverse reactions were scarce and were related to the admin-
istration procedure. All of them were short lasting and of mild 
or moderate intensity. 
  The results of AMELIA reveal that repeated cycles of intra-
articular injections of HA not only improve knee osteoarthritis 
symptoms during the in-between cycle period, but also exert a 
marked carry-over effect for at least 1 year after the last injec-
tions. In this regard, it is not possible to establish whether this 
carry-over effect reﬂ  ects a true disease remission or just a modi-
ﬁ  cation of the natural course of the disease.     
  AMELIA  Study  Group   J Toyos, Rheumatology Department, H Virgen Macarena, 
Sevilla; B Hernández-Cruz, Rheumatology Department, H Virgen Macarena, Sevilla; 
J Belzunegui, Rheumatology Department, Hospital Ntra Sra de Aránzazu, San 
Sebastián; S García, Rheumatology, Department, Hospital Puerta del Mar, Cádiz; 
M E Brito, Rheumatology Department, Hospital Ramón y Cajal, Madrid; 
J C Acebes, Rheumatology Department, Fundación Jiménez Díaz, Madrid; J L Guerra, 
  DISCUSSION 
  This study has assessed the efﬁ  cacy and safety of repeated intra-
articular injections of HA in knee osteoarthritis patients, show-
ing a symptomatic relief of pain and an improvement in function 
and patient global assessment during a follow-up period of 40 
months. At the end of the study, the percentage of responders 
according to OARSI 2004 criteria was 22% higher in the HA 
group than in the placebo group (p=0.004). 
  In recent years, consistent systematic reviews and meta-analy-
ses    10        21     –      26    have concluded that HA is superior to placebo in con-
trolling knee osteoarthritis symptoms.    24     –      26    Although a number of 
controlled studies have shown that this treatment is comparable 
in efﬁ  cacy to systemic forms of active intervention such as ste-
roids or NSAID,    22        23    some other studies have questioned the efﬁ  -
cacy of the treatment with HA.    21        27    The study design weaknesses 
and the enormous placebo effect in osteoarthritis clinical trials as 
well as the speciﬁ  c characteristics of the HA used can account 
for these contradictory results. There are two crucial aspects 
that have to be strongly considered in the design of clinical trials 
aimed to demonstrate a SYSADOA effect in osteoarthritis: the 
time when the analgesia starts and the duration of the carry-over 
effect. Furthermore, the various HA derivatives that are available 
on the market are synthesised using different methods and for-
mulated in different physical forms, and thus a uniform efﬁ  cacy 
and safety proﬁ  le should not be expected.    4        16        17        28    
  The starting time of the analgesic effect could not be well 
captured in some short-term clinical trials, and our study was 
not designed to address it. In fact, despite some patients going 
into remission at the ﬁ  rst assessment performed 7 months after 
the ﬁ  rst cycle, this effect could not be demonstrated, probably 
masked by the high efﬁ  cacy rates found in the placebo group at 
that time. However, the efﬁ  cacy of placebo remained quite stable 
throughout the study period, whereas the responder rate in the 
HA group increased, the differences being truly signiﬁ  cant from 
1 year onwards (p<0.05). Several randomised controlled trials 
in osteoarthritis failed to demonstrate the superiority of active 
treatment over placebo,    27        29     –      32    reaching efﬁ  cacy rates up to 60% 
even with orally administered placebos,    30    making it difﬁ  cult for 
the other treatments to surpass this level.    10    Moreover, the efﬁ  -
cacy of placebo has been conﬁ  rmed in osteoarthritis interven-
tions, and increases with the expectations of the patient with 
respect to the treatment and the use of invasive administration 
routes.    32    In AMELIA, however, the success of the study was in 
fact accentuated by the high placebo efﬁ  cacy detected, making 
the results found (80.5% of responders in the HA group at the end 
of follow-up compared with 65.8% for placebo patients), even 
  Table  3      Related  adverse  events  
       HA  (n=153)   Placebo  (n=153) 
Related adverse events 
(n (%))
    15 (9.8) 14 (9.1)
  Mild     7 (4.6) 12 (7.8)
  Moderate     8 (5.2) 2 (1.3)
     HA (n=153)    Placebo (n=153) 
  Mild    Moderate    Mild    Moderate 
Allergic reaction 2 (1.3) 
(1 rash, 1 swelling)
1 (0.7) 
(1 rash)
3 (1.9) 
(3 rash)
0
Pain at injection site 2 (1.3) 4 (2.6) 2 (1.3) 0
Bleeding at injection site 2 (1.3) 0 6 (3.9) 0
Arthralgia 0 2 (1.3) 1 (0.7) 1 (0.7)
Others 1 (0.7) 1 (0.7) 0 1 (0.7)
   HA,  hyaluronic  acid.   
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